Financial Data and Key Metrics Changes - Revenue for Q2 2025 totaled $51.3 million, representing a 16% increase year-over-year [5][30] - Adjusted EBITDA loss improved to $8.5 million from $12.1 million in Q1 2025 [7][35] - Cash usage decreased to $14.5 million from $21.2 million in the previous quarter [7][35] - Gross profit was $35.3 million, or 68.8% of revenue, up from 65.6% in the same period last year [31][32] - The company raised its revenue guidance for 2025 to a range of $208 million to $212 million, indicating a growth of 25% to 28% [6][37] Business Line Data and Key Metrics Changes - U.S. sales reached $10.3 million, exceeding previous guidance [5][30] - European direct market sales increased by approximately 27% this quarter, excluding currency effects [10][25] - Latin America saw mid-single-digit growth, with stabilization in Brazil and strong growth in Argentina [26] Market Data and Key Metrics Changes - U.S. accounted for 20% of global sales, while Europe, the Middle East, and Africa (EMEA) represented 40% [31] - Asia Pacific contributed 15% of sales, with year-over-year results down primarily due to challenges in China [31][32] Company Strategy and Development Direction - The company aims to achieve a leadership position in the U.S. market by leveraging superior product benefits and expanding its account base [8][12] - Focus on improving operational efficiency and profitability while advancing the innovation pipeline [40][41] - Plans to launch the Preservay procedure in 2026, which is expected to command a premium and expand the total addressable market (TAM) [23][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven by 2026 and expects the first positive EBITDA quarter later this year [12][38] - The U.S. market is showing strong momentum, with continued growth expected despite seasonal slowdowns [17][84] - Challenges in China are acknowledged, with management working closely with distribution partners to improve performance [11][50] Other Important Information - The Motiva Flora Smooth Silk tissue expander won innovation and safety awards, establishing it as a benchmark in breast reconstructive surgery [39] - The company is exploring refinancing options to reduce cash usage in the coming quarters [36] Q&A Session Summary Question: Can you provide more details on the assumptions behind the revenue guidance upgrade? - Management highlighted strong results in the U.S. and noted that China has been taken out of the guidance for the second half of the year due to challenges [46][49] Question: What is the growth trajectory for U.S. physician adds? - Management indicated that while they continue to add accounts, the focus will shift towards enhancing utilization rates in existing accounts [62][64] Question: How is the pricing trend in the U.S.? - The company maintains a premium pricing strategy and has not experienced significant pricing pressure [78] Question: What is the status of the investment from the distributor in China? - Management noted that the distributor is facing challenges in scaling operations, which has delayed expected progress [91][92] Question: How do Mia and Preserve compare in terms of future growth? - Management believes that Preserve will likely become larger than Mia due to its broader appeal to patients and surgeons [96][97]